comparemela.com

Latest Breaking News On - Isofol medical - Page 4 : comparemela.com

Invitation to presentation of Isofol s report for the first quarter of 2022

/PRNewswire/ Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol"), will publish the company s results for the first quarter of 2022 on Thursday,.

United kingdomVastra gotalands lanUlf jungneliusMerck cieIsofol medicalNasdaq stockholmChief executiveIsofol medical ab publ

Isofol initiates data assessment in Phase III colorectal cancer drug trial

Isofol Medical has initiated assessment of results from Phase III AGENT trial of arfolitixorin to treat metastatic colorectal cancer (mCRC).

Ulf jungneliusLaboratory equipmentElectronic data capture solutions for clinical trialsContract manufacturing organisationDrug administrationDrug processing technologyIsofol medicalNew drug applicationProcessing technologyData capture solutionsManufacturing organisationPharmaceutical supply

Isofol Medical : Full notice to attend the AGM 2022 (English)

Election of board members and auditor The nomination committee proposes re-election of Magnus Björsne, Robert Marchesani, Lennart Jeansson, Anna Belfrage, Alain Herrera,. | April 12, 2022

United statesVastra gotalands lanPaula boultbeeUlf jungneliusJan malmRobert marchesaniOla mannefredHans enocsonAlain herreraAnna belfrageLars lindAram mangasarianLennart jeanssonArvid wallgrensArvid wallgrens backeDocent of physiology at university gothenburg

Inflammatory Bowel Disease Market Is Anticipated to Progress at a CAGR of 8 0% in the APAC Region for the Study Period of 2018 to 2030, Estimates DelveInsight

Increasing cases of Inflammatory Bowel Disease (IBD) in various regions lead to increased demand for advanced diagnostic and treatment in the Inflammatory.

United statesSouth koreaEntyvio vedolizumabPrnewswire delveinsightEli lillyCelgene bristol myers squibbAzurrx biopharmaFalk pharma gmbTremfya guselkumabShruti thakurRedhill biopharmaFalk pharmaStelara ustekinumabCinrx pharmaZeposia ozanimodBristol myers squibb

Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

/PRNewswire/ Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug Administration (FDA) denied a request from the.

Vastra gotalands lanUlf jungneliusMerck kgaMerck kgaaDrug administrationNasdaq stockholmData safety monitoring boardInternational councilTechnical requirementsHuman useFast track designationChief executiveChief medicalIsofol medicalIsofol medical ab publ

vimarsana © 2020. All Rights Reserved.